Literature DB >> 22751540

In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates.

Céline Vidaillac1, Lothaire Benichou, Raphaël E Duval.   

Abstract

Colistin resistance, although uncommon, is increasingly being reported among Gram-negative clinical pathogens, and an understanding of its impact on the activity of antimicrobials is now evolving. We evaluated the potential for synergy of colistin plus trimethoprim, trimethoprim-sulfamethoxazole (1/19 ratio), or vancomycin against 12 isolates of Acinetobacter baumannii (n = 4), Pseudomonas aeruginosa (n = 4), and Klebsiella pneumoniae (n = 4). The strains included six multidrug-resistant clinical isolates, K. pneumoniae ATCC 700603, A. baumannii ATCC 19606, P. aeruginosa ATCC 27853, and their colistin-resistant derivatives (KPm1, ABm1, and PAm1, respectively). Antimicrobial susceptibilities were assessed by broth microdilution and population analysis profiles. The potential for synergy of colistin combinations was evaluated using a checkerboard assay, as well as static time-kill experiments at 0.5× and 0.25× MIC. The MIC ranges of vancomycin, trimethoprim, and trimethoprim-sulfamethoxazole (1/19) were ≥128, 4 to ≥128, and 2/38 to >128/2,432 μg/ml, respectively. Colistin resistance demonstrated little impact on vancomycin, trimethoprim, or trimethoprim-sulfamethoxazole MIC values. Isolates with subpopulations heterogeneously resistant to colistin were observed to various degrees in all tested isolates. In time-kill assays, all tested combinations were synergistic against KPm1 at 0.25× MIC and 0.5× MIC and ABm1 and PAm1 at 0.5× MIC. In contrast, none of the tested combinations demonstrated synergy against any colistin-susceptible P. aeruginosa isolates and clinical strains of K. pneumoniae isolates. Only colistin plus trimethoprim or trimethoprim-sulfamethoxazole was synergistic and bactericidal at 0.5× MIC against K. pneumoniae ATCC 700603. Colistin resistance seems to promote the in vitro activity of unconventional colistin combinations. Additional experiments are warranted to understand the clinical significance of these observations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22751540      PMCID: PMC3421898          DOI: 10.1128/AAC.05996-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.

Authors:  Jian Li; Craig R Rayner; Roger L Nation; Roxanne J Owen; Denis Spelman; Kar Eng Tan; Lisa Liolios
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Microbial Selection.

Authors:  V Bryson; W Szybalski
Journal:  Science       Date:  1952-07-18       Impact factor: 47.728

3.  In-vitro activity of cationic peptides alone and in combination with clinically used antimicrobial agents against Pseudomonas aeruginosa.

Authors:  A Giacometti; O Cirioni; F Barchiesi; M Fortuna; G Scalise
Journal:  J Antimicrob Chemother       Date:  1999-11       Impact factor: 5.790

4.  Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster.

Authors:  Anastasia Antoniadou; Flora Kontopidou; Garifalia Poulakou; Evangelos Koratzanis; Irene Galani; Evangelos Papadomichelakis; Petros Kopterides; Maria Souli; Apostolos Armaganidis; Helen Giamarellou
Journal:  J Antimicrob Chemother       Date:  2007-02-16       Impact factor: 5.790

5.  Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection.

Authors:  Simona Bratu; Mohamad Mooty; Satyen Nichani; David Landman; Carl Gullans; Barbara Pettinato; Usha Karumudi; Pooja Tolaney; John Quale
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

6.  Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea.

Authors:  Ji-Yoeun Suh; Jun Seong Son; Doo Ryeon Chung; Kyong Ran Peck; Kwan Soo Ko; Jae-Hoon Song
Journal:  Antimicrob Agents Chemother       Date:  2009-09-14       Impact factor: 5.191

Review 7.  The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria.

Authors:  Patrice Nordmann; Gaelle Cuzon; Thierry Naas
Journal:  Lancet Infect Dis       Date:  2009-04       Impact factor: 25.071

8.  Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains.

Authors:  Jian Li; Roger L Nation; Roxanne J Owen; Stephanie Wong; Denis Spelman; Clare Franklin
Journal:  Clin Infect Dis       Date:  2007-07-17       Impact factor: 9.079

9.  The lipid A biosynthesis mutation lpxA2 of Escherichia coli results in drastic antibiotic supersusceptibility.

Authors:  R Vuorio; M Vaara
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

10.  Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.

Authors:  Mark D Adams; Gabrielle C Nickel; Saralee Bajaksouzian; Heather Lavender; A Rekha Murthy; Michael R Jacobs; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

View more
  37 in total

1.  Co-Delivery of Ciprofloxacin and Colistin in Liposomal Formulations with Enhanced In Vitro Antimicrobial Activities against Multidrug Resistant Pseudomonas aeruginosa.

Authors:  Shaoning Wang; Shihui Yu; Yuwei Lin; Peizhi Zou; Guihong Chai; Heidi H Yu; Hasini Wickremasinghe; Nivedita Shetty; Junhong Ling; Jian Li; Qi Tony Zhou
Journal:  Pharm Res       Date:  2018-08-09       Impact factor: 4.200

2.  Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.

Authors:  Julien M Buyck; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

3.  Activity of the colistin-rifampicin combination against colistin-resistant, carbapenemase-producing Gram-negative bacteria.

Authors:  Marcela Nastro; Carlos Hernan Rodríguez; Renata Monge; Jonathan Zintgraff; Liliana Neira; Mirta Rebollo; Carlos Vay; Angela Famiglietti
Journal:  J Chemother       Date:  2013-12-06       Impact factor: 1.714

4.  In Vitro Bactericidal Activity of Trimethoprim-Sulfamethoxazole Alone and in Combination with Colistin against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates.

Authors:  Martha Nepka; Efstathia Perivolioti; Eleni Kraniotaki; Lida Politi; Athanasios Tsakris; Spyros Pournaras
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

5.  In Vitro and In Vivo Efficacy of an LpxC Inhibitor, CHIR-090, Alone or Combined with Colistin against Pseudomonas aeruginosa Biofilm.

Authors:  Jun Hou Tan; Celine Vidaillac; Joey Kuok Hoong Yam; Song Lin Chua; Michael Givskov; Liang Yang
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

Review 6.  Clinical Pharmacokinetics and Pharmacodynamics of Colistin.

Authors:  Nicolas Grégoire; Vincent Aranzana-Climent; Sophie Magréault; Sandrine Marchand; William Couet
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

Review 7.  Synergistic combinations of polymyxins.

Authors:  Justin R Lenhard; Roger L Nation; Brian T Tsuji
Journal:  Int J Antimicrob Agents       Date:  2016-10-24       Impact factor: 5.283

8.  Synergistic Effect of Colistin Combined with PFK-158 against Colistin-Resistant Enterobacteriaceae.

Authors:  Youwen Zhang; Xiukun Wang; Xue Li; Limin Dong; Xinxin Hu; Tongying Nie; Yun Lu; Xi Lu; Jing Pang; Guoqing Li; Xinyi Yang; Congran Li; Xuefu You
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

9.  Antibiotic combinations for controlling colistin-resistant Enterobacter cloacae.

Authors:  Thais Bergamin Lima; Osmar Nascimento Silva; Keyla Caroline de Almeida; Suzana Meira Ribeiro; Dielle de Oliveira Motta; Simone Maria-Neto; Michelle Brizolla Lara; Carlos Roberto Souza Filho; Alicia Simalie Ombredane; Celio de Faria Junior; Nadia Skorupa Parachin; Beatriz Simas Magalhães; Octávio Luiz Franco
Journal:  J Antibiot (Tokyo)       Date:  2016-07-06       Impact factor: 2.649

10.  Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria.

Authors:  Nicola Petrosillo; Maddalena Giannella; Massimo Antonelli; Mario Antonini; Bruno Barsic; Laura Belancic; Cagkan Inkaya A; Gennaro De Pascale; Elisabetta Grilli; Mario Tumbarello; Murat Akova
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.